TABLE 1.
Regulation of m6A modification in HNSCC.
| m6A Regulators | Target | Regulation in HNSCC | Function | Mechanisms |
|---|---|---|---|---|
| METTL3 Wu et al. (2021); Arumugam et al. (2021); Ai et al. (2021) | Circux1 Wu et al. (2021) | Up | writer | METTL3 promotes the m6A methylation level of Circux1 and increases the stability of its expression in hypopharyngeal squamous cell carcinoma (HPSCC) Wu et al. (2021) |
| PRMT5 and PD-L1 Ai et al. (2021) | Up | writer | METTL3 can promote the progress of OSCC by increasing the m6A editing degree of PRMT5 and PD-L1 Ai et al., 2021 | |
| METTL3 and METTL14 | LNCAROD | Up | writer | METTL3 and METTL14 can stabilize the expression of LNCAROD in HNSCC cells through m6A modification Ban et al., 2020 |
| RBM15 | TMBIM6 | Up | writer | RBM15 mediates the m6A modification of TMBIM6 and stabilizes the expression of TMBIM6 through IGF2BP3 Wang et al. (2021b) |
| KIAA1429 (VIRMA) | KIAA1429 | Up | writer | KIAA1429 (VIRMA) can be used as a “writer” of m6A to help overexpression of KIAA1429 mRNA Arumugam et al., 2021 |
| IGF2BP family (IGF2BP1, IGF2BP2 Geng et al., 2021; Paramasivam et al., 2021, IGF2BP3) | HMGA2 | Up | reader | The IGF2BP family promotes tumor progression by reading m6A-modified oncogenic mRNA Paramasivam et al., 2021 |
| TK1 | ||||
| HDGF | ||||
| FSCN1 | ||||
| MKI67 | ||||
| CD44 | ||||
| YTHDF1 Ye et al., 2020; Zhou et al., 2020 | Up | reader | The YTHDF1 methyltransferase domain can bind to the 3′UTR and 5′UTR of TRFC mRNA to promote m6A modification and translation of TFRC mRNA Ye et al., 2020 | |
| YTHDF2 Zhou et al., 2020 | ||||
| YTHDF3 Arumugam et al., 2021 | ||||
| YTHDC2 Zhou et al., 2020 | reader | |||
| ALKBH5 Shriwas et al., 2020 | FOXM1, NANOG (Shriwas et al., 2020) | Up | eraser | DDX3 directly regulates ALKBH5 to eliminate m6A methylation in the new transcripts of FOXM1 and NANOG Shriwas et al., 2020 |
| FTO Zhou et al., 2020; Paramasivam et al., 2021 | eraser | |||
| GRHL3-AS1, AL121845.4, AC116914.2, AL513190.1 | Down | GRHL3-AS1, AL121845.4, AC116914.2, AL513190.1 have a protective effect on HNSCC patients |